Literature DB >> 18004553

Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels.

Cristiana Rossi1, Luigi Alberto Pini, Maria Letizia Cupini, Paolo Calabresi, Paola Sarchielli.   

Abstract

BACKGROUND: Chronic migraine (CM) and medication-overuse headaches (MOH) are well-recognized disabling conditions affecting a significant portion of the headache population attending centers specialized in treating headaches. A dysfunctioning of the serotonergic system has been demonstrated in MOH and CM patients. Here we report on our assessment of the dysfunctioning of the endocannabinoid system as a potential underlying factor in pathogenic mechanisms involved in CM and MOH.
METHOD: To test the hypothesis of an impairment in the endocannabinoid system in patients with MOH and CM and to assess its relationship with any disruption of the serotonergic system, we determined the levels of the two main endogenous cannabinoids, anandamide (AEA) and 2-acylglycerol (2-AG), in platelets of 20 CM patients, 20 MOH patients and 20 control subjects and also measured the platelet serotonin levels in the same patients.
RESULTS: We found that 2-AG and AEA levels were significantly lower in MOH patients and CM patients than in the control subjects, without significant differences between the two patient groups. Serotonin levels were also strongly reduced in the two patient groups and were correlated with 2-AG levels, with higher values for MOH patients.
CONCLUSION: These data support the potential involvement of a dysfunctioning of the endocannabinoid and serotonergic systems in the pathology of CM and MOH. These systems appear to be mutually related and able to contribute to the chronification of both CM and MOH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004553     DOI: 10.1007/s00228-007-0391-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  47 in total

Review 1.  An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.

Authors:  Liana Fattore; M Sabrina Spano; Serena Deiana; Valeria Melis; Gregorio Cossu; Paola Fadda; Walter Fratta
Journal:  Brain Res Rev       Date:  2006-07-12

Review 2.  Endocannabinoids and drug dependence.

Authors:  Daniela Parolaro; Daniela Viganò; Tiziana Rubino
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2005-12

Review 3.  Involvement of the endocannabinoid system in drug addiction.

Authors:  Rafael Maldonado; Olga Valverde; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2006-02-17       Impact factor: 13.837

4.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

5.  Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.

Authors:  Simon Akerman; Philip R Holland; Peter J Goadsby
Journal:  J Pharmacol Exp Ther       Date:  2006-10-03       Impact factor: 4.030

6.  L-arginine/nitric oxide pathway activation in platelets of migraine patients with and without aura.

Authors:  V Gallai; A Floridi; G Mazzotta; M Codini; M Tognoloni; M R Vulcano; M Sartori; S Russo; A Alberti; F Michele; P Sarchielli
Journal:  Acta Neurol Scand       Date:  1996-08       Impact factor: 3.209

7.  5HT in migraine patients with medication-induced headache.

Authors:  R Hering; V Glover; K Pattichis; T Catarci; T J Steiner
Journal:  Cephalalgia       Date:  1993-12       Impact factor: 6.292

8.  Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.

Authors:  G Gobbi; F R Bambico; R Mangieri; M Bortolato; P Campolongo; M Solinas; T Cassano; M G Morgese; G Debonnel; A Duranti; A Tontini; G Tarzia; M Mor; V Trezza; S R Goldberg; V Cuomo; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

9.  Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.

Authors:  Aline Quartilho; Heriberto P Mata; Mohab M Ibrahim; Todd W Vanderah; Frank Porreca; Alexandros Makriyannis; T Philip Malan
Journal:  Anesthesiology       Date:  2003-10       Impact factor: 7.892

Review 10.  Medication-overuse headache: a worldwide problem.

Authors:  Hans-Christoph Diener; Volker Limmroth
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

View more
  27 in total

Review 1.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 2.  Dependent behavior in patients with medication-overuse headache.

Authors:  Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2012-02

3.  Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine.

Authors:  Simon Akerman; Philip R Holland; Michele P Lasalandra; Peter J Goadsby
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

4.  Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial.

Authors:  Arão Belitardo Oliveira; Reinaldo Teixeira Ribeiro; Marco Tulio Mello; Sergio Tufik; Mario Fernando Prieto Peres
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-09

Review 5.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

6.  Predictive index for the onset of medication overuse headache in migraine patients.

Authors:  T Onaya; M Ishii; H Katoh; S Shimizu; H Kasai; M Kawamura; Y Kiuchi
Journal:  Neurol Sci       Date:  2013-01       Impact factor: 3.307

Review 7.  Serotonin and migraine: a reconsideration of the central theory.

Authors:  Alessandro Panconesi
Journal:  J Headache Pain       Date:  2008-07-31       Impact factor: 7.277

8.  Possible Anandamide and Palmitoylethanolamide involvement in human stroke.

Authors:  Marcello Naccarato; Daniela Pizzuti; Stefania Petrosino; Marco Simonetto; Laura Ferigo; Fabio Chiodo Grandi; Gilberto Pizzolato; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2010-05-14       Impact factor: 3.876

9.  Fatty acids, membrane viscosity, serotonin and ischemic heart disease.

Authors:  Massimo Cocchi; Lucio Tonello; Giovanni Lercker
Journal:  Lipids Health Dis       Date:  2010-09-08       Impact factor: 3.876

Review 10.  Medication-overuse headache: risk factors, pathophysiology and management.

Authors:  Hans-Christoph Diener; Dagny Holle; Kasja Solbach; Charly Gaul
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.